SCHEMBL21169208

SCHEMBL21169208

CC(C)C(C)N1C(=O)NC(C)(C)C1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.43
KMT2A Q03164 3/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
AR P10275 2/20 0.35
MEN1 O00255 2/20 0.35
TSHR P16473 2/20 0.35
LMNA P02545 1/20 0.35
PDE4A P27815 1/20 0.33
PDE4B Q07343 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE4D Q08499 1/20 0.33
HSD17B10 Q99714 1/20 0.33
TOP2A P11388 1/20 0.31
TOP2B Q02880 1/20 0.31
ALDH1A1 P00352 1/20 0.31
MAPT P10636 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
KDM4E B2RXH2 1/20 0.31
PADI4 Q9UM07 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12042277 0.82 POLB (0.46) POLBKMT2AL3MBTL1ARMEN1
SCHEMBL11384762 0.78 POLB (0.43) POLBKMT2AL3MBTL1ARMEN1
SCHEMBL1159787 0.76 POLB (0.45) POLBKMT2AL3MBTL1ARMEN1
SCHEMBL13745559 0.75 POLB (0.45) POLBKMT2AL3MBTL1ARMEN1
SCHEMBL1513862 0.72 POLB (0.42) POLBKMT2AL3MBTL1ARMEN1
SCHEMBL2135683 0.70 POLB (0.36) POLBKMT2AL3MBTL1ARMEN1
SCHEMBL10422398 0.69 POLB (0.44) POLBKMT2AL3MBTL1ARMEN1
SCHEMBL4408725 0.69 L3MBTL1 (0.50) POLBKMT2AL3MBTL1MEN1TSHR
SCHEMBL4945315 0.66 POLB (0.40) POLBKMT2AL3MBTL1ARMEN1
SCHEMBL11165303 0.65 POLB (0.36) POLBKMT2AL3MBTL1MEN1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10870657-B2 Compounds for the treatment of cancer and inflammatory disease SHY Therapeutics LLC (US) 2020-12-22 US disclosed
US-20190218229-A1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMTORY DISEASE SHY Therapeutics LLC 2019-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190218229-A1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMTORY DISEASE MAPK1, MAPK6, MAP3K1 POLB 1722/4885KMT2A 3181/4885L3MBTL1 4409/4885
US-10870657-B2 Compounds for the treatment of cancer and inflammatory disease MAPK6, MAP3K6, MAPK4 POLB 1589/4885KMT2A 3544/4885L3MBTL1 4204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.